Philadelphia Trust Company’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$277K Buy
7,550
+50
+0.7% +$2.37K 0.02% 222
2025
Q4
$382K Hold
7,500
0.03% 184
2025
Q3
$416K Hold
7,500
0.03% 169
2025
Q2
$518K Hold
7,500
0.04% 150
2025
Q1
$521K Hold
7,500
0.04% 149
2024
Q4
$645K Hold
7,500
0.05% 138
2024
Q3
$893K Hold
7,500
0.06% 127
2024
Q2
$1.07M Hold
7,500
0.08% 111
2024
Q1
$963K Hold
7,500
0.08% 119
2023
Q4
$776K Hold
7,500
0.07% 123
2023
Q3
$682K Hold
7,500
0.07% 129
2023
Q2
$607K Hold
7,500
0.06% 143
2023
Q1
$597K Hold
7,500
0.06% 142
2022
Q4
$508K Hold
7,500
0.05% 150
2022
Q3
$374K Hold
7,500
0.04% 168
2022
Q2
$418K Hold
7,500
0.04% 157
2022
Q1
$416K Hold
7,500
0.03% 178
2021
Q4
$420K Hold
7,500
0.03% 183
2021
Q3
$360K Hold
7,500
0.03% 188
2021
Q2
$314K Hold
7,500
0.02% 202
2021
Q1
$253K Hold
7,500
0.02% 204
2020
Q4
$262K Hold
7,500
0.02% 193
2020
Q3
$260K Buy
+7,500
New +$250K 0.03% 180
2015
Q3
Sell
-510
Closed -$4.66K 179
2015
Q2
$4.66K Buy
+510
New +$14.3K 0.02% 166

Other funds holding NVO

Philadelphia Trust Company's NVO Position: Q1 2026 in Review

Philadelphia Trust Company increased its Novo Nordisk (NVO) stake by 0.67% in Q1 2026, buying an estimated $2.37K and bringing the position to 7,550 shares worth $277K. The position accounts for 0.02% of the portfolio, ranked #222.

Philadelphia Trust Company first reported a position in NVO in Q2 2015 and has held it in 24 quarters since. The position peaked at $1.07M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Philadelphia Trust Company held 7,550 shares of Novo Nordisk worth $277K as of Q1 2026.
  • Philadelphia Trust Company bought 50 Novo Nordisk shares in Q1 2026, an estimated $2.37K.
  • Novo Nordisk made up 0.02% of Philadelphia Trust Company's portfolio in Q1 2026, its #222 holding.
  • Philadelphia Trust Company first reported a position in Novo Nordisk in Q2 2015 and has held it in 24 quarters since.
  • Philadelphia Trust Company's Novo Nordisk position peaked at $1.07M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Philadelphia Trust Company's 13F filing for Q1 2026, filed 13 May 2026.